Focusing on clinical DevelopmenT & commercialization
Seattle Genetics is a biotechnology company advancing a broad pipeline of antibody-based therapies. In August 2011, the U.S. Food and Drug Administration (FDA) granted accelerated approval of ADCETRIS™ (brentuximab vedotin) for two indications.

We are jointly developing brentuximab vedotin in collaboration with Millennium: The Takeda Oncology Company. Under the collaboration, Seattle Genetics has full commercialization rights to brentuximab vedotin in the U.S. and Canada. We plan to submit our regulatory application to Canadian Health authorities in the first half of 2012 for relapsed Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL). Millennium has exclusive rights to commercialize the product candidate in all other countries. In June 2011, the European Medicines Agency (EMA) accepted for review Millennium's Marketing Authorization Application (MAA) for ADCETRIS for the treatment of relapsed or refractory HL and relapsed or refractory systemic ALCL.

robust product pipeline
In addition to ADCETRIS, Seattle Genetics has three clinical-stage ADC product candidates, SGN-75, ASG-5ME and
ASG-22ME, which are in phase I trials. We are also advancing a pipeline of promising preclinical candidates and have robust research and development capabilities that are our engine for innovation and long-term growth.

ADC Technology Empowers Monoclonal Antibodies
Seattle Genetics has developed next generation ADCs that link the proven selectivity and activities of monoclonal antibodies with potent cytotoxic agents. Our proprietary technology employs synthetic tumor cell-killing agents called auristatins (such as MMAE and MMAF) and stable linkers that attach the auristatin to the antibody. Our linker systems are designed to be stable in the bloodstream and release the cell-killing agent once inside targeted cancer cells. This approach is intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially enhancing antitumor activity.

Expanding Our Opportunities Through Collaboration
Collaborating with leading biopharmaceutical companies is a cornerstone of Seattle Genetics' business strategy. Product-focused collaborations, such as our collaboration agreement with Millennium: The Takeda Oncology Company to globally develop and commercialize brentuximab vedotin, provide significant near- and mid-term funding while bringing in additional resources and expertise to support, advance and expand promising development programs. Collaboration and license agreements around our proprietary ADC technology also generate cash for the company - more than $165 million to date - while providing further clinical validation of the ADC platform and, in some cases, opening the door to new product development opportunities.

View our ADC collaborations pipeline >